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ceutical Companies (VFA) was established to outline the regulatory re-
quirements, the experience gathered with inspections by means of a
survey and to set up guidance on how to manage an inspection. 3 Bayer Schering Pharma AG,
Berlin, Germany Results and conclusions: The survey, conducted with the help of
15 pharmaceutical companies within the VFA, included a total of 224 4 Sanofi Aventis Deutschland
GmbH, Berlin, Germany inspections (74 inspections in Germany, 150 from other European
countries).MostfrequentfindingsinandoutsideGermanywererelated
to “documentation” (40.5% vs. 21.3%), “investigational new drugs”
(16.2% vs. 14.7%), “drug safety” (13.5% vs. 8%) and “application for a
clinical trial authorization” (5.4% vs. 12%).
From a German perspective, key findings of this working group were
the necessity for a clear differentiation of responsibilities between na-
tional and federal as well as international authorities, a harmonization
of inspection procedures and topics, and a clarification of whether pre-
study/on-study and pre-approval/post-approval GCP inspections of the
federal higher authority are included in the “Zentralstelle der Länder
für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten” (ZLG)
requirements. The survey illustrated, that inspections usually are con-
ducted at the investigational site, and that most of the findings are well
known and thus could be prevented by communicating and discussing
auditresultsmoreintenselywithinstudygroups.Again,thesurveyillus-
trated, that a harmonization of inspections appears warranted. Finally
acodeofpracticeisprovidedthatconsidersthesefindingsanddelivers
a basis for a successful inspection whether at the sponsor or the GCP
site.
Keywords: GCP inspection, Implementation Directive 2001/20/EC,
frequency, survey, sponsor inspection, code of practice
Zusammenfassung
Hintergrund: Mit Implementierung der „Clinical Trials“ Direktive
2001/20/EGsowieder„GoodClinicalPractice“Direktive2005/28/EG
wurdedieDurchführungvonklinischenPrüfungeninEuropaumfassend
neugeregeltundharmonisiert.GCP-Inspektionensindeinwesentlicher
Bestandteil dieser Regelungen und betreffen Prüfstellen, Labore,
SponsorenundAuftragsinstitute(contractresearchorganizations,CROs)
gleichermaßen.HäufigfehltesjedochaneinemallgemeinenVerständnis
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sind.
Methoden: Eine Arbeitsgruppe des Unterausschusses Klinische For-
schung/QualitätssicherungdesVFA(VerbandForschenderArzneimittel-
hersteller) erstellte eine Übersicht der regulatorischen Anforderungen
zu GCP-Inspektionen, erfasste Erfahrungen mit Inspektionen mittels
einer Umfrage und erarbeitete einen Leitfaden zur Begleitung einer
GCP-Sponsor-Inspektion.
Ergebnisse und Schlussfolgerung: Die Umfrage, die mit Unterstützung
von15imVFAorganisiertenpharmazeutischenUnternehmendurchge-
führt wurde, umfasste eine Gesamtzahl von 224 Inspektionen (74 In-
spektionen in Deutschland, 150 aus anderen europäischen Ländern).
DiehäufigstenBefundeinnerhalbundaußerhalbDeutschlandsbezogen
sich auf die „Dokumentation“ (40,5% vs. 21,3%), „Prüfmedikation“
(16,2% vs. 14,7%), „Arzneimittelsicherheit“ (13,5% vs. 8%) und den
„Antrag auf Genehmigung der klinischen Prüfung“ (5,4% vs. 12%).
AusdeutscherSichtsinddiewichtigstenErkenntnissederArbeitsgruppe
die Notwendigkeit einer klaren Abgrenzung der Verantwortlichkeiten
zwischen lokalen, nationalen und internationalen Behörden, eine Har-
monisierung der Inspektionsdurchführung und -inhalte, sowie eine
Klärung ob die ‚pre-study/on-study’ und ‚pre-approval/post-approval’
GCP-Inspektionen der Oberbehörden den von der „Zentralstelle der
LänderfürGesundheitsschutzbeiArzneimittelnundMedizinprodukten”
(ZLG)vorgelegtenAnforderungenentsprechen.DieUmfrageergab,dass
Inspektionen routinemäßig an Prüfstellen durchgeführt werden; die
meisten Inspektionsbefunde sind bekannt und könnten durch eine
verbesserte Kommunikation und Diskussion der Befunde mit den Stu-
diengruppen vermieden werden. Die Umfrage bestätigte auch, dass
eine Harmonisierung der Inspektionen notwendig erscheint. Abschlie-
ßendwirdeinLeitfadenunterBerücksichtigungderUmfrageergebnisse
vorgestellt,deralsBasisfürdieerfolgreicheBegleitungeinerBehörden-
Sponsor- oder Prüfstellen-Inspektion verwendet werden kann.
Schlüsselwörter: GCP-Inspektion, Implementierung der Direktive
2001/20/EG, Häufigkeit, Umfrage, Sponsor-Inspektion, Leitfaden
Introduction
The ICH directive E6 defines “Good Clinical Practice“ as
“a standard for the design, conduct, performance,
monitoring, auditing, recording, analyses, and reporting
of clinical trials that provides assurance that the data
and reported results are credible and accurate, and that
theright,integrity, andconfidentialityoftrialsubjectsare
protected” (ICH E6, glossary 1.24 [1]). The efficiency of
these measures is ensured by internal audits by the
sponsor (ICH E6, glossary 1.6 [1]) and external inspec-
tions by the authorities (ICH E6, glossary 1.29 [1]).
In the course of the Clinical Trials Directive 2001/20/EC
implementation by the 12
th amendment to the German
Medicines Law (Deutsches Arzneimittelgesetz) and the
GCP regulation in 2004 external inspections by the
higher authorities were fundamentallyrevised. Since the
interpretationoftheseregulationsissubjecttocontinuous
refinement,itisessentialforresearch-basedpharmaceut-
ical companies to be sure about the expectations of au-
thoritiesand to be aware of the specific conductof these
GCP inspections.
ThereforeaworkinggroupoftheClinicalResearch/Quality
Assurance subcommittee of the German Association of
Research-Based Pharmaceutical Companies (Verband
ForschenderArzneimittelhersteller,VFA)wasestablished
to
1. compile an overview about existing guidelines, laws
and regulations
2. compile the hitherto experience with GCP sponsor
inspectionsafterimplementationoftheClinicalTrials
Directive 2001/20/EC
3. developacodeofpracticeforexpertassistanceduring
GCP sponsor inspections.
Overviewaboutexistingguidelines,
laws and regulations
The European Medicines Evaluation Agency (EMEA) was
founded in 1993 based on the order 2309/93/EC to
provideacentralizedEuropeanlicensingandsupervision
procedure for pharmaceutical drugs. Article 51 of this
order specifies “that co-ordinating the verification of
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tice” is one important task of the EMEA.
TocomplywiththisorderaGCPInspectionServicesGroup
was founded in 1997 by the EMEA to advise and support
thecommunity,thecommissions,thememberstatesand
the EMEA in issues regarding GCP and inspections. The
working group consists of GCP inspectors from member
states and the chairman is recruited from within the
EMEA-section for inspections. As of July 2007 this group
was renamed into GCP Inspectors Working Group (GCP
IWG)andadetaileddescriptionofthemandate,theaims
and regulations of this working group was provided [2].
Attachment 1 gives an overview about the European dir-
ectives and international rules considering GCP inspec-
tions. It took more than 10 years and several revisions
of the respective orders until specific requirements for
inspectors and descriptions of the procedures were
published within the guidance 2005/28/EC in 2005. In
chapter IV of the EUDRALEX Volume 10, published in
2006, prerequisites for GCP inspectors and the conduct
ofGCPinspectionswerelaiddownindetail.TheGCPIWG
published a description of how to coordinate, prepare,
conductandreportGCPinspectionswithinthecentralized
licensingprocedureontheEMEAhomepageinMay2008
[3]. The description contains detailed information on the
content and extent of inspections at the investigational
sites,laboratories,sponsor’ssite,clinicalresearchorgan-
izations (CROs), phase-I-units, as well as computer sys-
tems, file structure and archiving.
The implementation of the European legislation into na-
tionalGermanlawisdisplayedinAttachment2.Inprepar-
ing this table the respective paragraphs of the German
Medicines Law (Arzneimittelgesetz, AMG) and the GCP
order (GCP-Verordnung, GCP-V) were combined. The
situation in Germany is special in that there is a task
sharing between the federal higher authority and local
authorities within federal states. The federal higher au-
thority is responsible for approving clinical trials and li-
censing pharmaceuticals. The federal state authorities
areresponsibleforroutineorcausespecificsupervisions
ofsponsors,investigationalsitesorotherinstitutionsand
are confederated since 1994 (Zentralstelle der Länder
für Gesundheitsschutz bei Arzneimitteln und Medizin-
produkten, ZLG).
A description of the different types of inspections in Ger-
many can be found in the General Administrative Fiat for
Conductingthe MedicinesLaw (Allgemeine Verwaltungs-
vorschrift zur Durchführung des Arzneimittelgesetzes,
AMGVwV)[4].Detailedandpubliclyaccessibleprocedural
instructions regarding inspections of clinical trials of
pharmaceutical drugs which are subject to authorization
have been published by the ZLG on their website in
2007/2008 [5].
Attachment3containsfurtherhelpfulandpubliclyaccess-
ibleinformationsourcesregardingGCPinspections.Highly
recommended is the EMEA website containing among
other Standard Operating Procedures (SOP) for GCP in-
spection issues [6]. Of particular interest for sponsors
based in Germany is the ZLG website [7], which provides
a detailed and excellently rehashed overview of national
and international regulations as well as links to interna-
tional and national authorities.
Takentogetherandinreviewingtheavailableinformation
thefollowingissuesaredesirablefromthesponsor’sside:
1. a clear differentiation of responsibilities between na-
tionalandfederalaswellasinternationalauthorities,
2. a harmonization of inspection procedures and topics
arewarrantedwhencomparingdifferentfederalstate
authorities, in particular for Germany. An identical in-
terpretationofGCPlawsandguidelinesismandatory.
A first step into this direction has been undertaken
by formation of the ZLG and their publicly available
procedural requirements. A guideline on how to inter-
prettheseproceduralrequirementsishoweveressen-
tial.
3. It remains unclear whether these procedural require-
mentsalsoincludepre-study/on-studyandpre-approv-
al/post-approval GCP inspections of the federal
higher authority.
Ideally a continuous dialogue between authorities and
sponsorsregardingthecorrectinterpretationoftheregu-
latory basis of GCP and the resulting steps for improving
qualityshouldbeestablishedaimingatimprovingclinical
research and patient safety in Germany.
Experience with GCP sponsor
inspections – results of a survey in
Germany and Europe
PubliclyavailablereportsofGCPinspectionsarerare[8],
[9],[10]andmostlyfromGreatBritain.Thereforeasurvey
was conducted between January 2005 and June 2007
among 45 pharmaceutical companies organized within
theVFA(GermanAssociationofResearch-BasedPharma-
ceutical Companies) to determine the frequency, type,
reasonandthereportedfindingsofGCPandpharmacovi-
gilance inspections after the directive 2001/20/EC at
investigationalandsponsorsitesinGermanyandEurope
(fordetailedinformationsee[11]).Despitetworeminders,
only15companies–mostofthemmemberoftheClinical
Research/Quality Assurance subcommittee – provided
anevaluablequestionnaire.Thisreflectsaresponserate
of 33.3% within the VFA, who represents more than 2/3
of the German pharmaceutical market and research
activities. The companies reported a total of 224 inspec-
tions (74 inspections in Germany, 150 from other
European countries). This corresponds to an inspection
rateofabout50peryear(GCPsiteinspections>sponsor
inspections). Of note, the survey only included clinical
trialsperformedbythepharmaceuticalindustryanddoes
notreflectthesituationofinvestigatorinitiatedresearch,
which might be different.
The questionnaire asked for information about all GCP
sponsor, GCP site and pharmacovigilance inspections
within Europe starting 2005. Specifically we asked for
thetypeofinspection,theresponsibleinspectingauthority
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(BfArM), Paul-Ehrlich-Institut (PEI), Medicines and
Healthcare products Regulatory Agency (MHRA), local
authority), the reason for the inspection (e.g. Pre-Clinical
Trial Application,pre-approval, for cause, routine) and for
the findings of the inspection.
The frequency of sponsor inspections and inspections at
theinvestigationalsitedifferssubstantiallywhencompar-
ingGermanytotherestofEurope(Figure1).Remarkable
was, that no combined inspections were conducted in
Germany, while this was the case for 12% of inspections
in Europe. Investigational site inspections were most
frequentbothinGermanyandEurope.Pharmacovigilance
inspections have a low share (10% of total) of the total
inspections (8/74 in Germany; 15/150 in Europe).
From 73 out of 224 reported inspections a total of 184
findingswerereported.Therangeoffindingsisdisplayed
in Figure 2. Most frequent findings in and outside Ger-
manywererelatedto“documentation”(40.5%vs.21.3%),
“investigational new drugs” (16.2% vs. 14.7%), “drug
safety” (13.5% vs. 8%) and “application for a clinical trial
authorization” (5.4% vs. 12%).
Results classified as related to “documentation” include
instructions for preparing the Case Report Form (e.g.
naming the total number of pages, verification of every
singlein-andexclusioncriterion,frequencyofinvestigator
signatures), the completeness of physician’s document-
ation (GCP compliant corrections of the CRF, locating the
patients’ informed consent and emergency envelopes,
completeness of medical history within the patient’s
documentation), missing documents (e.g. investigators
brochure, monitoring report), disposition of source docu-
ments (quality of life questionnaires), and CRF copies at
the investigational site, traceability of trial approval
(mostly in case of amendments).
Results classified as related to “investigational new
drugs” include the necessity of labeling in case of pro-
longed storage life of medication, uniformity of the la-
beling text in case of multi-lingual labels, access to and
storage of investigational drugs, clarity of medication
tracking and improvements of temperature control (if
necessary).
Results related to “drug safety” were adherence to
deadlines and their documentation in case of severe ad-
verseeventsandsuspicionofunexpectedseriousadverse
eventsaswellasthereportingofnon-seriouseventsand
their documentation.
Results related to “application for a clinical trial au-
thorization”includenon-appropriateuseoftheinvestiga-
tor definition, the late submission of amendments, poor
patient information and missing recent certificates of in-
surance at ethics committees and authorities but also
themissingdocumentationofethicscommitteecompos-
ition.
Findingsfrompharmacovigilanceinspections(3/8inspec-
tions in Germany and 7/15 in Europe) were: improved
compliance with reporting deadlines, faster contact to
the authorities in case of newly recognized safety con-
cerns, an improved training for contract partners, the
continuous reachability for questions relating to drug
safety and improved database applications. In addition
tothesetheavailabilityandcontentofstandardoperating
procedures(SOP)wasafurtherfindinginotherEuropean
countries.
Taken together these are the most important survey res-
ults:
1. GCP site inspections were much more frequent than
sponsor inspections
2. In Germany inspections are (as opposed to other
Europeancountries)conductedbyavarietyofauthor-
ities. Of note, recentlythe numberof localauthorities
in North Rhine-Westphalia was reduced from 59 to 1
central authority for this Federal State.
3. Most findings from these inspections are well known
and could be addressed to the sites in order to avoid
them in the future.
4. TheGermanDrugLawusesaninconclusivedefinition
of the “investigator”, leading to the obscure situation
that every physician involved may be regarded to be
an “investigator”, resulting in everyday practice in
some under- and/or overreporting to concerned au-
thorities and Ethics Committees.
Code of practice for expert
assistance during GCP sponsor
inspections
Table 1 displays the items of a GCP sponsor inspection
which were derived from a recent international GCP
sponsorinspectionandfromfurthersourcesliketheZLG
procedural requirements “Procedures for inspections in
clinical trials subject to authorization on pharmaceutical
drugs”.Theabilitytogeneralizeishoweverrestricteddue
to different internal organizations and thus the code of
practice has to be adapted to prepare for an inspection.
The following steps are necessary for the preparation,
conduct and follow-up of an inspection.
Preparation
In the course of the written notification of a GCP inspec-
tion a number of information regarding the company are
requested.Theseincludeorganizationalcharts,overviews
of ongoing or completed studies within a particular time
frameandlistsofstandardoperatingprocedures.Adraft
agenda may be provided.
Additional documents that may be requested before the
inspectioninclude:completedquestionnaire,listofSOPs
as well as provision of selected SOPs, list of used and
validated computer systems (including validation docu-
ments for a particular system), description of archives
used, contract templates, certificate of insurance. While
the inspection date is usually not negotiable, the agenda
may have room for discrete changes.
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Figure 2: Findings from site inspections (from a survey of VFA companies in Germany [11])
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Table 1: Scope and content of a GCP sponsor inspection
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following: short presentation to introduce the company
(20 min), recent organizational charts, identification of
staff for interviews and training for the participants (usu-
ally staff that conducts the trial), up to date curriculum
vitae, recent SOP (ensuring that staff is familiar with
these), expert translator if necessary, logistical organiza-
tion (meeting room, copy machine, telephone, fax and IT
infrastructure).
Conduct (example)
At the first day of the inspection frequently there is a
commonmeetingwithinspectorsandstaffofthesponsor.
Duringthecourseofthismeetingtheinspectorsillustrate
the reason for the inspection (legal requirements). The
company then has room for a short introduction before
the final agenda is agreed upon and logistic questions
answered.Attheworkplaceoftheinspector(s)thefollow-
ing material has to be provided: organizational charts for
all departments subject to inspection, the most relevant
clinicalandpharmacovigilanceSOP,curriculumvitae,job
descriptions, training documentation for interview part-
ners, trial master file, contracts, case report forms and
others. These and all documents that are requested
during inspection should be labelled to be confidential
and every single item recorded. The inspectors will read
throughthedocumentsprovidedandconductaconsider-
able number of interviews. It is also important to record
thequestionsduringtheinterview(usuallytaskofQuality
Assurance).Documentsrequestedbytheinspectorshave
to be delivered as soon as possible.
The active phase of the GCP inspection ends with a dis-
cussion, at which the inspectors summarize and assess
theessentialresultsandthecompanyhastheopportunity
to explain these. Again a detailed protocol is mandatory.
Follow-up
Inspections require as much time for follow-up as for
preparation. The information constitute an independent
feedbackwhichishighlywelcometoimprovetheinternal
organization. The following steps are very important: for-
ward pending documents to the inspectors, analyze the
orally presented results, prepare the comments to the
authority and the workup, in case of serious findings ini-
tiate the appropriate measures, prepare investigational
sites for a subsequent inspection, and answer to the in-
spection report and the actions derived from that. Most
authorities grade the results as “minor”, “major” or “crit-
ical”. Further findings can be categorized into “Non-
compliances”,“Recommendations”and“Observations”.
Conclusions
The implementation of the "Clinical Trials" Directive
2001/20/EC and the "Good Clinical Practice" Directive
2005/28/ECfundamentallyrestructuredandharmonized
the conduct of clinical trials in Europe. GCP inspections
– which affect study sites, laboratories, sponsors and
contract research organizations (CROs) alike – make up
an important part of the regulations laid down in these
directives.
The publication of the procedures for conducting GCP
inspections by the EMEA GCP Inspectors Working Group
and the publication of procedures for inspections of clin-
ical trials of medicinal products by the German Central
Authority of the federal states for Health Protection with
Regard to Medicinal Products and Medical Devices have
helped increase transparency and harmonization [5].
There is however room for a differential interpretation of
these guidelines and guidance on how to apply these is
warranted. This is particularly important in countries like
Germanyinwhichmanydifferentauthoritiesinteractand
perform GCP inspections. A close dialogue between the
competent authorities and the sponsor about the inter-
pretation of fundamental regulatory requirements with
regard to GCP would improve the quality of clinical re-
search and reduce the uncertainties when being inspec-
ted by different authorities.
The survey on GCP inspections at the sponsor’s site or-
ganizedwithintheVFAontheotherhandshowedarather
consistentpictureofinspectionfrequency,siteofconduct
and important findings. It is the more surprising that key
learnings from these inspections are obviously not used
toimprovetheresultsofsubsequentinspections;results
of repeated inspections are frequently quite similar. A
more intense follow-up and interchange between com-
panies should allow to raise the awareness for the most
salient points and thus increase the quality of clinical
trial conduct. The provided guidance may represent an
essential step into this direction.
Taken together Germany, after the "Clinical Trials" Direct-
ive 2001/20/EC, has further strengthened its position
as a competitive location for clinical research. This can
be demonstrated by the increasing number of clinical
studies in Germany and the excellent quality of its inves-
tigational sites.
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